For example, MSCs‐EVs can induce angiogenesis and modulate immune signaling, as well as strong tissue repair;[24] EVs from immune cells contain major histocompatibility complex (MHC), which can induce or inhibit specific immune responses; tumor‐derived EVs show an extremely strong homing ability but may also lead to tumor progression and metastasis; and platelet‐derived EVs have a natural affinity to damaged sites in the vessel wall.[25] Therefore, the source of their donor cells is also worthy of primary consideration when employing EV therapy. This evidence concerns the gene HLA-C and neoplasm.